Aspen Pharmacare Holdings Limited (JSE:APN)

Market Cap	52.47B
Revenue (ttm)	45.53B
Net Income (ttm)	4.48B
Shares Out	444.21M
EPS (ttm)	10.08
PE Ratio	11.71
Forward PE	10.22
Dividend	3.59 (3.03%)
Ex-Dividend Date	Sep 18, 2024

Volume	1,231,820
Average Volume	1,228,565
Open	11,810
Previous Close	11,811
Day's Range	11,546 - 11,848
52-Week Range	10,575 - 25,296
Beta	0.42
RSI	42.88
Earnings Date	Sep 3, 2025

About Aspen Pharmacare Holdings

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names. It also offers such as sleeping aid, thyroid hormone, immunosuppressant, iron supplement, analgesic ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1850
• Employees: 9,350
• Stock Exchange: Johannesburg Stock Exchange
• Ticker Symbol: APN

Financial Performance

In 2024, Aspen Pharmacare Holdings's revenue was 44.71 billion, an increase of 9.82% compared to the previous year's 40.71 billion. Earnings were 4.40 billion, a decrease of -15.76%.